A transformer model applied to spatial transcriptomics mapped fine-grained mouse-brain tissue domains and revealed hundreds of regions absent from existing anatomical atlases. The study evaluated the data-driven domains against the Allen Mouse Brain Common Coordinate Framework and reported strong alignment alongside the novel subdivisions.
Technology: CellTransformer
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: The study evaluated the data-driven domains against the Allen Mouse Brain Common Coordinate Framework and reported strong alignment alongside the novel subdivisions.
- Still unknown: The new domains are data-driven subdivisions; their biological meaning and generalization beyond the analyzed mouse-brain dataset require further study. Nature's paper page was accessible in search and as a PDF abstract, but its HTML reader view redirected to a cookie wall.
- AI role: The transformer analyzed cell-neighborhood patterns in spatial transcriptomics and assigned tissue domains without manual annotation; human researchers compared outputs with the Allen reference atlas.
Evidence sources: https://www.nature.com/articles/s41467-025-64259-4
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 16 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
Random-forest models trained on UCSF records (749 expert-diagnosed Alzheimer’s disease cases and 250,545 controls) identified clinical features predictive up to seven years before the recorded onset; the seven-year model’s AUROC was 0.72 using clinical features alone. Matched-cohort follow-up in external University of California health-system records found faster Alzheimer’s diagnosis after osteoporosis in women. Genetic colocalization analyses supported a female-specific shared signal between Alzheimer’s disease, low heel bone mineral density and MS4A6A expression near the MS4A gene cluster. The paper also reports shared APOE-locus support for hyperlipidemia and Alzheimer’s disease.
Technology: Random-forest models on longitudinal electronic health records, interpreted with the SPOKE biomedical knowledge network
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Matched-cohort follow-up in external University of California health-system records found faster Alzheimer’s diagnosis after osteoporosis in women.
- Still unknown: This is hypothesis-generating observational work. EHR features may reflect healthcare access, clinician behavior, coding and biological processes; the authors explicitly state that further validation across omics data types is needed. Genetic colocalization and matched cohort associations do not establish that osteoporosis causes Alzheimer’s disease or that treating osteoporosis prevents it. The prediction model is not a prospective clinical-impact evaluation, and early risk discrimination is modest with the low-prevalence outcome.
- AI role: Random-forest models ranked EHR-derived clinical features associated with future Alzheimer’s diagnosis. The team used matched models to prioritize hypotheses, then used SPOKE to connect clinical predictors to biological networks and independent health-system data plus GWAS/eQTL colocalization to examine the osteoporosis and hyperlipidemia associations. The model-generated prioritization led to follow-up of the female-specific osteoporosis signal near MS4A6A.
Evidence sources: https://www.nature.com/articles/s43587-024-00573-8.pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 101 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A recurrent model of RNA-sequence features helped nominate RNA-binding proteins involved in secretion. Perturbation and binding experiments supported RBM24 involvement in the tested cell system, alongside previously implicated factors. This mechanism study was public in an April 2023 preprint before the 2024 journal version. It does not establish a universal secretion mechanism, in-vivo benefit or a therapeutic result.
Technology: ExoGRU gated recurrent neural network
Publication: Preprint · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Preprint
- Test type: direct test
- Tested: Selected factors received perturbation and extracellular RNA-binding follow-up.
- Still unknown: Generality across cell types and effects in vivo remain unestablished.
- AI role: ExoGRU gated recurrent neural network supported the stated study; experimental and interpretive work remained with researchers.
Evidence sources: https://www.biorxiv.org/content/10.1101/2023.04.04.535452v1 · https://api.biorxiv.org/details/biorxiv/10.1101/2023.04.04.535452 · https://pmc.ncbi.nlm.nih.gov/articles/PMC11019361/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 16 Nov 2026. Review scope: Primary bioRxiv API v1 metadata/abstract and journal PMC selected model, validation and limitations text; supplement not reviewed..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
A machine-learning feature-selection pipeline integrated public whole-blood (1,885 samples) and synovial-tissue (284 samples) transcriptomic datasets and selected a 13-gene rheumatoid-arthritis score. Across five independent transcriptomic datasets, the score tracked DAS28 disease activity, distinguished rheumatoid arthritis from osteoarthritis, separated polyarticular juvenile idiopathic arthritis from healthy controls, and was associated with treatment effects. In an independent immunoblot cohort, two of six tested proteins, TNFAIP6/TSG-6 and HSP90AB1/HSP90, were confirmed.
Technology: Cross-tissue machine-learning feature-selection pipeline for transcriptomic data
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In an independent immunoblot cohort, two of six tested proteins, TNFAIP6/TSG-6 and HSP90AB1/HSP90, were confirmed.
- Still unknown: The transcriptomic inputs were previously published datasets and the reported clinical associations are observational; the study does not establish a deployable diagnostic test or causal disease mechanism. The independent protein follow-up confirmed two of six proteins tested, not the entire 13-gene panel, and validation in larger prospective cohorts is needed. Treatment-effect association should not be interpreted as prospective prediction of individual response.
- AI role: The pipeline selected a compact 13-gene signature from public blood and synovial expression datasets; the study evaluated its association with disease activity and diagnostic distinctions across five independent transcriptomic datasets, then tested six selected proteins by immunoblot in a separate patient cohort.
Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.638066/pdf
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 47 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.
An ensemble of neural networks trained on 107,823 fetal ultrasound images reached an AUC of 0.99, 95% sensitivity and 96% specificity in an internal test set of 4,108 fetal surveys with 0.9% CHD. Its sensitivity was comparable to that of clinicians and it stayed robust on outside-hospital and lower-quality images. Caveat: retrospective study with a low-prevalence internal test set.
Technology: Ensemble of convolutional neural networks with segmentation models
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: Trained on 107,823 images from 1,326 retrospective studies; on 4,108 fetal surveys (0.9% CHD), AUC 0.99, 95% sensitivity, 96% specificity, 100% negative predictive value; comparable to clinicians and robust on outside-hospital images.
- Still unknown: Prospective screening performance is not reported in the abstract.
- AI role: An ensemble of neural networks identifies cardiac views and classifies normal versus complex congenital heart disease.
Evidence sources: https://doi.org/10.1038/s41591-021-01342-5
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 345 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 4/5 · Validation 2/5 · Novelty 4/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.